Company Overview and News

 
Lightbridge’s Jim Malone to Speak at World Nuclear Fuel Cycle Conference

2018-04-18 globenewswire
RESTON, Va., April 18, 2018 (GLOBE NEWSWIRE) -- Lightbridge Corporation (NASDAQ:LTBR), a nuclear fuel technology company, today announced that Jim Malone, Chief Fuel Development Officer, is scheduled to speak at the World Nuclear Fuel Cycle conference on April 19. Organized by the Nuclear Energy Institute and World Nuclear Association, the World Nuclear Fuel Cycle Conference is an international forum taking place in Madrid from April 17-19.
Upvote Downvote

 
Lightbridge Corporation Technology Featured in Leading Scientific Journal; Article Highlights Nonproliferation Benefits of Lightbridge’s Metallic Fuel

2018-04-16 globenewswire
RESTON, Va., April 16, 2018 (GLOBE NEWSWIRE) -- Lightbridge Corporation’s (NASDAQ:LTBR), a nuclear fuel technology company, today announced that a peer-reviewed paper published in a leading scientific journal examines the nonproliferation benefits of Lightbridge’s metallic fuel. Entitled "Proliferation resistant plutonium: An updated analysis," the paper appears in the April 15 edition of Nuclear Engineering and Design, an international journal affiliated with the European Nuclear Society that is devoted to all aspects of nuclear fission energy.
Upvote Downvote

 
Lightbridge to Present at The MicroCap Conference on April 10th in New York City

2018-04-03 accesswire
RESTON, VA / ACCESSWIRE / April 3, 2018 / Lightbridge Corporation (NASDAQ: LTBR), a nuclear fuel technology company, today announced that James Malone, Chief Nuclear Fuel Development Officer, will present at this year's MicroCap Conference on April 10th at 2:00 PM ET at the Essex House in New York City.
Upvote Downvote

 
LTBR / Lightbridge Corp. FORM 8-K (Current Report)

2018-03-30 sec.gov
ltbr_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

 
LTBR / Lightbridge Corp. 424B2 (Prospectus)

2018-03-30 sec.gov
ltbr_424b2.htm Filed pursuant to Rule 424(b)(2) Registration Statement No. 333-223674 PROSPECTUS SUPPLEMENT (To Prospectus Dated March 23, 2018) LIGHTBRIDGE CORPORATION $50,000,000
Upvote Downvote

 
LTBR / Lightbridge Corp. FORM 10-K/A (Annual Report)

2018-03-30 sec.gov
ltbr_10ka.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

 
LTBR / Lightbridge Corp. DEF 14A

2018-03-29 sec.gov
ltbr_def14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

 
Lightbridge Chairman Thomas Graham to Speak at Erasmus University Nonproliferation Conference

2018-03-22 globenewswire
RESTON, Va., March 22, 2018 (GLOBE NEWSWIRE) -- Ambassador Thomas Graham, Executive Chairman of Lightbridge Corporation (NASDAQ:LTBR), is scheduled to speak on nuclear nonproliferation issues with two other leading experts in The Hague, Netherlands on March 23 at 5:00 p.m. Central European Time. Sponsored by the Erasmus University Rotterdam School of Social and Behavioral Sciences and the Netherlands Ministry of Foreign Affairs, the associated conference in Rotterdam focuses on their roles in the successful efforts in 1995 to permanently extend in force the Nuclear Nonproliferation Treaty (NPT) and how the nuclear political landscape has evolved.
Upvote Downvote

 
LTBR / Lightbridge Corp. DEL AM

2018-03-20 sec.gov
ltbr_delam.htm March 20, 2018 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549
Upvote Downvote

 
Lightbridge CEO to Present at the 4th Annual Gabelli & Company Waste Services Symposium in New York City

2018-03-20 globenewswire
RESTON, Va., March 20, 2018 (GLOBE NEWSWIRE) -- Lightbridge Corporation (NASDAQ:LTBR), a nuclear fuel technology company, today announced that Seth Grae, CEO of Lightbridge, will present at 1:15 pm ET at the 4th Annual Gabelli & Company Waste Services Symposium being held on Friday, March 23rd at the Lotte New York Palace in New York City. During the presentation, Seth Grae will discuss the proliferation resistance of spent nuclear fuel using Lightbridge technology, as well as how Lightbridge’s nuclear fuel reduces the amount of waste while creating clean energy that does not contribute to air pollution and has no CO2 emissions.
Upvote Downvote

 
LTBR / Lightbridge Corp. null

2018-03-19 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0W(# @;V)J#3P\+TQI;F5A
Upvote Downvote

1
Lightbridge's (LTBR) CEO Seth Grae On Q4 2017 Results - Earnings Call Transcript

2018-03-16 seekingalpha
Greetings and welcome to the Lightbridge 2017 Fourth Quarter Earnings and Business Update Conference Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder this conference is being recorded.
Upvote Downvote

 
LTBR / Lightbridge Corp. FORM 8-K (Current Report)

2018-03-15 sec.gov
ltbr_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

 
LTBR / Lightbridge Corp. FORM S-3

2018-03-15 sec.gov
ltbr_s3.htm As filed with the Securities and Exchange Commission on March 15, 2018 Registration No. 333-
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 53224K104